Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
DEJourney Medical Corporation logo

Journey Medical Corporation (DERM)

NASDAQ Capital Market · Currency in USD
$5.02 ▼ -0.07 (-1.38%)
At close: Oct 23, 4:00 PM ET. Market closed.
$5.02 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$5.09
Open
$5.05
Day's Range
$4.82 – $5.06
52 Week Range
$4.31 – $9.56
Volume
157,139
Avg. Volume
227,315
Market Cap
$141.69M
Beta (5Y Monthly)
1.11
PE Ratio (TTM)
--
EPS (TTM)
-$0.22
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$11.75

Profile: Journey Medical Corporation

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
58
CEO
Claude Maraoui

Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate $0.02 · Revenue est. $21.42M
DateEst.Actual
Aug 12, 2026-$0.02-$0.01Beat
May 13, 2026-$0.07-$0.08Miss
Mar 25, 2026-$0.06-$0.04Beat
Nov 12, 2025-$0.08-$0.09Miss
Aug 12, 2025-$0.07-$0.16Miss
May 14, 2025-$0.24-$0.18Beat

Analyst view

Consensus price target
$11.75 ▲ +134.1%
Range $10.50 – $13.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on DERM and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.